Semaglutide
Semaglutide (GLP-1 Receptor Agonist)
The appetite regulator
An FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management (Ozempic, Wegovy). Semaglutide reduces appetite centrally, slows gastric emptying, and improves insulin sensitivity. Notably, it is NOT metabolized by CYP enzymes — response variation is driven by receptor genetics, not liver metabolism.
Key Benefits
Clinically proven weight loss of 15-17% body weight (STEP trials)
Reduced appetite and food cravings via central GLP-1R activation
Improved glycemic control and insulin sensitivity
Cardiovascular risk reduction (SELECT trial, FDA-approved indication)
Sustained effects with weekly dosing due to albumin binding half-life
Mechanism of Action
How Semaglutide works
Semaglutide mimics the incretin hormone GLP-1 through multiple coordinated pathways:
- Central appetite suppression — activates GLP-1 receptors in the hypothalamus and brainstem (nucleus tractus solitarius), reducing hunger signaling and increasing satiety. This is the primary driver of weight loss
- Delayed gastric emptying — slows stomach emptying by 20-30%, prolonging post-meal fullness and reducing caloric intake per meal
- Enhanced insulin secretion — glucose-dependent insulin release from pancreatic beta cells. Only triggers when blood glucose is elevated, minimizing hypoglycemia risk
- Glucagon suppression — reduces hepatic glucose output by suppressing glucagon from alpha cells, improving fasting glucose and HbA1c
- Cardiovascular benefit — SUSTAIN-6 and SELECT trials demonstrated reduced major adverse cardiovascular events (MACE), independent of weight loss
Your Genetics & Semaglutide
Genetic variants that affect your response
These SNPs determine how effectively Semaglutide works for you specifically. A genetic peptide report identifies your variants before you start.
The Ala316Thr variant affects GLP-1 receptor signaling efficiency. Thr316 carriers show altered receptor internalization kinetics, potentially requiring dose adjustment. This variant has been associated with differential weight loss response in clinical cohorts.
The strongest common genetic risk factor for type 2 diabetes. T-allele carriers have impaired beta-cell insulin secretion. Semaglutide's glucose-dependent insulin release may partially compensate for this deficit, but glycemic response magnitude varies by genotype.
Beta-arrestin 1 mediates GLP-1 receptor internalization and desensitization after activation. Variants affecting ARRB1 expression influence how quickly receptors are recycled, potentially affecting sustained response to semaglutide over months of treatment.
Proprotein convertase 1 processes proglucagon into active GLP-1. Variants reducing PCSK1 activity lower endogenous GLP-1 production — these individuals may be particularly responsive to exogenous GLP-1R activation by semaglutide.
Which variants do you carry?
Upload your DNA data or order a kit to find out.
Evidence & Research
200+
Published studies
Multiple human clinical trials or CPIC-level pharmacogenomic data
Common Stacks
Semaglutide is commonly combined with:
Frequently Asked Questions
Is semaglutide affected by CYP enzyme genetics?
No. Unlike most drugs, semaglutide is NOT metabolized by cytochrome P450 (CYP) enzymes. It is degraded by general proteolytic enzymes after albumin dissociation. This means CYP2D6, CYP3A4, and other pharmacogenomic CYP variants do not affect semaglutide levels or dosing — a major advantage for genetic predictability.
What genetics affect semaglutide response?
GLP1R variants (rs6923761) affect receptor sensitivity and weight loss magnitude. TCF7L2 (rs7903146) influences the glycemic improvement component. ARRB1 variants affect receptor recycling and long-term efficacy. These are receptor-level and pathway-level genetics rather than metabolism genetics.
How much weight loss can semaglutide produce?
The STEP clinical trials showed average weight loss of 15-17% of body weight over 68 weeks at the 2.4mg weekly dose. However, individual response varies significantly — from 5% to over 25% — driven partly by GLP1R receptor genetics and baseline metabolic status. A genetic report can help predict where you fall on this spectrum.
Learn More About Semaglutide
Personalize your protocol
Does Semaglutide match your DNA?
Upload your existing genetic data or order a kit. Your report scores Semaglutide against your unique genetic profile — CYP metabolism, receptor variants, pathway markers — in minutes.